28 results on '"Serebruany, Victor L."'
Search Results
2. Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges
3. Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The cangrelor efficacy challenge
4. Viewpoint: “Underutilisation of novel antiplatelet agents – myths, generics, and economics”
5. Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention
6. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials – Common patterns in TRITON, RECORD, and PLATO?
7. Mortality and cancer after 12 versus 30 months dual antiplatelet therapy
8. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease
9. Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers
10. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation
11. Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges
12. Viewpoint: “Underutilisation of novel antiplatelet agents – myths, generics, and economics”
13. Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The cangrelor efficacy challenge
14. Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention
15. Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes
16. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel
17. Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel
18. Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
19. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease
20. Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers
21. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials – Common patterns in TRITON, RECORD, and PLATO?
22. The TRITON versus PLATO trials: Differences beyond platelet inhibition
23. Future of oral antiplatelet therapy: Four challenged hypotheses
24. The Relations of Major Platelet Receptor Expression during Myocardial Infarction. Monitoring Efficacy of GPIIb/IIIa Inhibitors by Measuring P-selectin?
25. Monitoring Platelet Inhibition during Chronic Oral Platele Glycoprotein IIb/IIIa Blockade: Are We Missing Somethintg?
26. Take an Aspirin or Have a Drink: Antecedent Aspirin and Moderate Alcohol Consumption Similarly Affect Baseline Platelet Characteristics in Patients with Acute Myocardial Infarction
27. Reteplase but not Alteplase Affects Early Soluble PECAM-1 and P-selectin Release in Patients with Acute Myocardial Infarction
28. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.